Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
50
PGNY Quote, Financials, Valuation and Earnings
Last price:
$23.02
Seasonality move
:
-4.47%
Day range:
$22.60 - $23.34
52-week range:
$13.39 - $30.42
Dividend yield:
0%
P/E ratio:
40.39x
P/S ratio:
1.78x
P/B ratio:
4.22x
Volume:
794K
Avg. volume:
1.1M
1-year change:
-23.27%
Market cap:
$2B
Revenue:
$1.2B
EPS (TTM):
$0.57
Analysts' Opinion
-
Consensus RatingProgyny has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 5 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $26.25, Progyny has an estimated upside of 14.03% from its current price of $23.02.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $21.00 representing 100% downside risk from its current price of $23.02.
Fair Value
-
According to the consensus of 10 analysts, Progyny has 14.03% upside to fair value with a price target of $26.25 per share.
PGNY vs. S&P 500
-
Over the past 5 trading days, Progyny has underperformed the S&P 500 by -3.26% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Progyny does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Progyny has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Progyny reported revenues of $324M.
Earnings Growth
-
Progyny has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Progyny reported earnings per share of $0.17.
Enterprise value:
1.7B
EV / Invested capital:
--
Price / LTM sales:
1.78x
EV / EBIT:
23.49x
EV / Revenue:
1.42x
PEG ratio (5yr expected):
3.42x
EV / Free cash flow:
8.77x
Price / Operating cash flow:
11.04x
Enterprise value / EBITDA:
22.40x
Gross Profit (TTM):
$266.8M
Return On Assets:
7.52%
Net Income Margin (TTM):
4.33%
Return On Equity:
11.16%
Return On Invested Capital:
11.16%
Operating Margin:
7.46%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $873.1M | $1.1B | $1.2B | $278.1M | $324M | |
| Gross Profit | $193M | $242.6M | $266.8M | $62.4M | $75.8M | |
| Operating Income | $38.4M | $65.7M | $73.1M | $18.5M | $24.2M | |
| EBITDA | $40.2M | $68.2M | $76.7M | $19.2M | $25.3M | |
| Diluted EPS | $0.43 | $0.61 | $0.57 | $0.17 | $0.17 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $227.8M | $309M | $527.1M | $681.5M | $567.7M | |
| Total Assets | $294.6M | $415.5M | $649.7M | $794.3M | $730.3M | |
| Current Liabilities | $101M | $128.7M | $206.9M | $205.9M | $237.1M | |
| Total Liabilities | $110M | $135.9M | $225.3M | $222.7M | $263.1M | |
| Total Equity | $184.6M | $279.6M | $424.4M | $571.6M | $467.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $112.6M | $193.6M | $203.2M | $25.7M | $49.8M | |
| Cash From Investing | $11.8M | -$197.3M | $81.8M | $19.3M | -$94.6M | |
| Cash From Financing | -$7.9M | -$36.6M | -$285.8M | -$27.4M | -$3.3M | |
| Free Cash Flow | $108.9M | $190.3M | $195.8M | $24.9M | $47M | |
PGNY
Sector
Market Cap
$2B
$34.4M
Price % of 52-Week High
75.68%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
14.45%
-1.01%
1-Year Price Total Return
-23.27%
-37.36%
Beta (5-Year)
1.307
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$23.26
200-day SMA
Buy
Level
$19.69
Bollinger Bands (100)
Buy
Level
21.06 - 22.92
Chaikin Money Flow
Buy
Level
3.2M
20-day SMA
Buy
Level
$22.17
Relative Strength Index (RSI14)
Buy
Level
56.24
ADX Line
Buy
Level
36.14
Williams %R
Neutral
Level
-44.086
50-day SMA
Buy
Level
$21.92
MACD (12, 26)
Buy
Level
6.36
25-day Aroon Oscillator
Buy
Level
44
On Balance Volume
Sell
Level
-321.9K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (7.9949)
Buy
CA Score
(Annual)
Level (1.6424)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-1.9693)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (7)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Progyny Inc is a benefits management company specializing in fertility, family building, and women's health benefits solutions. Its clients include employers across various industries. The fertility benefits solution consists of treatment services (Smart Cycles), access to the Progyny network of high-quality fertility specialists that perform the Smart Cycle treatments, and active management of the selective network of high-quality provider clinics.
Stock Forecast FAQ
In the current month, PGNY has received 5 Buy ratings 5 Hold ratings, and 0 Sell ratings. The PGNY average analyst price target in the past 3 months is $26.25.
-
Where Will Progyny Stock Be In 1 Year?
According to analysts, the consensus estimate is that Progyny share price will rise to $26.25 per share over the next 12 months.
-
What Do Analysts Say About Progyny?
Analysts are divided on their view about Progyny share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Progyny is a Sell and believe this share price will drop from its current level to $21.00.
-
What Is Progyny's Price Target?
The price target for Progyny over the next 1-year time period is forecast to be $26.25 according to 10 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 5 analysts rate the stock a Hold.
-
Is PGNY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Progyny is a Leans Bullish. 5 of 10 analysts rate the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of PGNY?
You can purchase shares of Progyny via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Progyny shares.
-
What Is The Progyny Share Price Today?
Progyny was last trading at $23.02 per share. This represents the most recent stock quote for Progyny. Yesterday, Progyny closed at $23.02 per share.
-
How To Buy Progyny Stock Online?
In order to purchase Progyny stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 18
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
